Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223

Giandomenico Roviello, Rosj Gallicchio, Giovanni Bozza, Maria Grazia Rodriquenz, Michele Aieta, Giovanni Storto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

© 2019 Roviello et al. Background: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. Patients and methods: Patients with histologically confirmed progressive CRPC with two or more bone metastases and symptomatic disease were eligible. Previous therapy with a novel hormonal therapy was allowed. The patients received six intravenous injections of radium-223 every 4 weeks. A visual analog scale (VAS) was adopted to evaluate patients’ basal pain. Results: A total of 25 patients were evaluated. Of these, 6 (24%) reported VAS,4. After a median follow-up of 8 months, all patients died with a median overall survival of 8.3 months (95% CI: 5.2–11.8 months), 12.6 months in the patients with VAS,4 vs 6.6 months in the patients with VAS $4 (P=0.03). Conclusion: The present study suggests that VAS could be prognostic of the survival of mCRPC treated with radium-223 irrespective of the limitations of a small number of patients and the retrospective nature of the data.
Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalOncoTargets and Therapy
Volume12
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Radium
Castration
Prostatic Neoplasms
Pain
Survival
Visual Analog Scale
Intravenous Injections
Therapeutics
Neoplasm Metastasis
Bone and Bones

Keywords

  • Pain
  • Prostate cancer
  • Radioactive therapy
  • Radium-223

Cite this

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. / Roviello, Giandomenico; Gallicchio, Rosj; Bozza, Giovanni; Rodriquenz, Maria Grazia; Aieta, Michele; Storto, Giovanni.

In: OncoTargets and Therapy, Vol. 12, 01.01.2019, p. 9-13.

Research output: Contribution to journalArticle

@article{93889c1fc4f04713998a4066688d2041,
title = "Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223",
abstract = "{\circledC} 2019 Roviello et al. Background: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. Patients and methods: Patients with histologically confirmed progressive CRPC with two or more bone metastases and symptomatic disease were eligible. Previous therapy with a novel hormonal therapy was allowed. The patients received six intravenous injections of radium-223 every 4 weeks. A visual analog scale (VAS) was adopted to evaluate patients’ basal pain. Results: A total of 25 patients were evaluated. Of these, 6 (24{\%}) reported VAS,4. After a median follow-up of 8 months, all patients died with a median overall survival of 8.3 months (95{\%} CI: 5.2–11.8 months), 12.6 months in the patients with VAS,4 vs 6.6 months in the patients with VAS $4 (P=0.03). Conclusion: The present study suggests that VAS could be prognostic of the survival of mCRPC treated with radium-223 irrespective of the limitations of a small number of patients and the retrospective nature of the data.",
keywords = "Pain, Prostate cancer, Radioactive therapy, Radium-223",
author = "Giandomenico Roviello and Rosj Gallicchio and Giovanni Bozza and Rodriquenz, {Maria Grazia} and Michele Aieta and Giovanni Storto",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/OTT.S174206",
language = "English",
volume = "12",
pages = "9--13",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223

AU - Roviello, Giandomenico

AU - Gallicchio, Rosj

AU - Bozza, Giovanni

AU - Rodriquenz, Maria Grazia

AU - Aieta, Michele

AU - Storto, Giovanni

PY - 2019/1/1

Y1 - 2019/1/1

N2 - © 2019 Roviello et al. Background: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. Patients and methods: Patients with histologically confirmed progressive CRPC with two or more bone metastases and symptomatic disease were eligible. Previous therapy with a novel hormonal therapy was allowed. The patients received six intravenous injections of radium-223 every 4 weeks. A visual analog scale (VAS) was adopted to evaluate patients’ basal pain. Results: A total of 25 patients were evaluated. Of these, 6 (24%) reported VAS,4. After a median follow-up of 8 months, all patients died with a median overall survival of 8.3 months (95% CI: 5.2–11.8 months), 12.6 months in the patients with VAS,4 vs 6.6 months in the patients with VAS $4 (P=0.03). Conclusion: The present study suggests that VAS could be prognostic of the survival of mCRPC treated with radium-223 irrespective of the limitations of a small number of patients and the retrospective nature of the data.

AB - © 2019 Roviello et al. Background: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. Patients and methods: Patients with histologically confirmed progressive CRPC with two or more bone metastases and symptomatic disease were eligible. Previous therapy with a novel hormonal therapy was allowed. The patients received six intravenous injections of radium-223 every 4 weeks. A visual analog scale (VAS) was adopted to evaluate patients’ basal pain. Results: A total of 25 patients were evaluated. Of these, 6 (24%) reported VAS,4. After a median follow-up of 8 months, all patients died with a median overall survival of 8.3 months (95% CI: 5.2–11.8 months), 12.6 months in the patients with VAS,4 vs 6.6 months in the patients with VAS $4 (P=0.03). Conclusion: The present study suggests that VAS could be prognostic of the survival of mCRPC treated with radium-223 irrespective of the limitations of a small number of patients and the retrospective nature of the data.

KW - Pain

KW - Prostate cancer

KW - Radioactive therapy

KW - Radium-223

UR - http://www.scopus.com/inward/record.url?scp=85059448933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059448933&partnerID=8YFLogxK

U2 - 10.2147/OTT.S174206

DO - 10.2147/OTT.S174206

M3 - Article

AN - SCOPUS:85059448933

VL - 12

SP - 9

EP - 13

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -